Future study is necessary to confirm whether DUSP5 expression is elevated in models of AD/ADRD, and whether the downregulation of DUSP5 expression or the use of DUSP5 inhibitors, such as compounds containing a naphthalene trisulfonate core, [63] or halogenated xanthene inhibitors of DUSP5, can enhance CBF and cognitive function in individuals with AD/ADRD [64]. The gene discussed is CEBPZ; the disease is Alzheimer disease.